



# NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

---

**Date:** November 6, 2009

**To:** Primary Clinical Research Associates

**From:** Angie Patterson-LaBaw  
Research Protocol Specialist

**Re:** N0747: A Randomized Phase II Trial of Sunitinib Plus Capecitabine Versus Capecitabine Alone (with the potential for crossover) for Elderly and/or Poor Performance Status Patients with Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction

The On-Study Form has been updated as follows:

<b>Form title</b>	<b>Brief description of change</b>
On-Study Form	<ul style="list-style-type: none"><li>Modified MedDra code: <b>Read:</b> 10030157 (Gastrointestinal Neoplasm, "Gastroesophageal Cancer," "Esophagus Cancer, NOS") <b>Now reads:</b> 10030139 (Adenocarcinoma of the esophagus) or 10066354 (Adenocarcinoma of the gastroesophageal junction)</li><li>Removed "Primary Tumor Site" question.</li></ul>

If you have any questions, please feel free to contact me.

Enclosure